Restriction-Assembly: A Solution to Construct Novel Adenovirus Vector.
Gibson assembly
adenovirus
construct
infectious clone
modification
restriction enzyme
vector
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
06 03 2022
06 03 2022
Historique:
received:
24
01
2022
revised:
24
02
2022
accepted:
01
03
2022
entrez:
26
3
2022
pubmed:
27
3
2022
medline:
15
4
2022
Statut:
epublish
Résumé
Gene therapy and vaccine development need more novel adenovirus vectors. Here, we attempt to provide strategies to construct adenovirus vectors based on restriction-assembly for researchers with little experience in this field. Restriction-assembly is a combined method of restriction digestion and Gibson assembly, by which the major part of the obtained plasmid comes from digested DNA fragments instead of PCR products. We demonstrated the capability of restriction-assembly in manipulating the genome of simian adenovirus 1 (SAdV-1) in this study. A PCR product of the plasmid backbone was combined with SAdV-1 genomic DNA to construct an infectious clone, plasmid pKSAV1, by Gibson assembly. Restriction-assembly was performed repeatedly in the steps of intermediate plasmid isolation, modification, and restoration. The generated adenoviral plasmid was linearized by restriction enzyme digestion and transfected into packaging 293 cells to rescue E3-deleted replication-competent SAdV1XE3-CGA virus. Interestingly, SAdV1XE3-CGA could propagate in human chronic myelogenous leukemia K562 cells. The E1 region was similarly modified to generate E1/E3-deleted replication-defective virus SAdV1-EG. SAdV1-EG had a moderate gene transfer ability to adherent mammalian cells, and it could efficiently transduce suspension cells when compared with the human adenovirus 5 control vector. Restriction-assembly is easy to use and can be performed without special experimental materials and instruments. It is highly effective with verifiable outcomes at each step. More importantly, restriction-assembly makes the established vector system modifiable, upgradable and under sustainable development, and it can serve as the instructive method or strategy for the synthetic biology of adenoviruses.
Identifiants
pubmed: 35336953
pii: v14030546
doi: 10.3390/v14030546
pmc: PMC8954691
pii:
doi:
Substances chimiques
DNA
9007-49-2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Curr Gene Ther. 2011 Oct;11(5):363-74
pubmed: 21888620
Viruses. 2020 Mar 11;12(3):
pubmed: 32168853
Semin Immunol. 2020 Aug;50:101430
pubmed: 33262065
Exp Hematol. 2006 Sep;34(9):1171-82
pubmed: 16939810
Expert Rev Vaccines. 2019 Jun;18(6):597-613
pubmed: 31132024
J Virol. 2004 Dec;78(23):13207-15
pubmed: 15542673
BMC Biotechnol. 2019 Apr 24;19(1):23
pubmed: 31014302
J Virol Methods. 2018 Jul;257:85-92
pubmed: 29703616
J Virol. 2001 Jun;75(11):5288-301
pubmed: 11333910
J Biotechnol. 2020 Jan 10;307:193-201
pubmed: 31751597
Lancet. 2008 Nov 29;372(9653):1881-1893
pubmed: 19012954
Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2509-14
pubmed: 9482916
J Virol. 2018 Feb 26;92(6):
pubmed: 29298888
Hum Vaccin Immunother. 2018 Jul 3;14(7):1679-1685
pubmed: 29300685
J Virol. 1996 Jul;70(7):4805-10
pubmed: 8676512
J Gen Virol. 2005 Jun;86(Pt 6):1681-1686
pubmed: 15914845
Hum Gene Ther. 2014 Apr;25(4):285-300
pubmed: 24499174
Nucleic Acids Res. 2004 Jul 07;32(12):e98
pubmed: 15240836
Cancers (Basel). 2020 May 02;12(5):
pubmed: 32370135
Virus Res. 2019 Jul 15;268:1-10
pubmed: 31108113
J Gen Virol. 2021 Mar;102(3):
pubmed: 33625352
Cancer Sci. 2017 May;108(5):831-837
pubmed: 28266780
Expert Rev Vaccines. 2017 Dec;16(12):1241-1252
pubmed: 29047309
Virus Evol. 2021 Mar 02;7(1):veab018
pubmed: 33732504
Anal Biochem. 1992 Nov 1;206(2):231-5
pubmed: 1280006
J Virol. 2003 Aug;77(15):8263-71
pubmed: 12857895
Vaccine. 2016 Nov 4;34(46):5579-5586
pubmed: 27682509
Methods Mol Biol. 2000;135:515-23
pubmed: 10791346
Front Immunol. 2020 May 19;11:909
pubmed: 32508823
Trends Pharmacol Sci. 2012 Aug;33(8):442-8
pubmed: 22621975
J Gene Med. 2004 Jun;6(6):631-41
pubmed: 15170734
Int J Cancer. 2004 Jul 1;110(4):475-80
pubmed: 15122578
J Virol Methods. 2011 Aug;175(2):188-96
pubmed: 21601594
Immune Netw. 2021 Feb 15;21(1):e6
pubmed: 33728099
Biotechniques. 1998 May;24(5):760-2
pubmed: 9591124
Methods Cell Sci. 2000 Mar;22(1):63-6
pubmed: 10650336
Arch Virol. 2012 Jul;157(7):1313-21
pubmed: 22527861
Hum Gene Ther. 2019 Jun;30(6):777-791
pubmed: 30793964
Hum Gene Ther. 2007 Sep;18(9):849-60
pubmed: 17767401
Hum Vaccin Immunother. 2014;10(10):2875-84
pubmed: 25483662
Curr Opin Virol. 2021 Jun;48:49-56
pubmed: 33892224
FEBS Lett. 2019 Dec;593(24):3609-3622
pubmed: 31758807
J Gene Med. 2009 Feb;11(2):128-38
pubmed: 19097028
Blood Adv. 2019 Oct 8;3(19):2883-2894
pubmed: 31585952
Hum Gene Ther. 2014 Jan;25(1):3-11
pubmed: 24444179
ACS Nano. 2021 Sep 28;15(9):13970-13979
pubmed: 34415739
Nat Methods. 2009 May;6(5):343-5
pubmed: 19363495
Curr Protoc Mol Biol. 2016 Jan;113(1):16.26.1-16.26.18
pubmed: 31773916
Rev Med Virol. 2009 May;19(3):165-78
pubmed: 19367611
Nucleic Acids Res. 2015 Apr 30;43(8):e50
pubmed: 25609697